Close Menu

NEW YORK – Cyteir Therapeutics on Thursday said it has closed an oversubscribed $80 million Series C financing round and that it will use the funds to take its lead synthetic lethal compound CYT-0851 into Phase II trials.

The financing was led by RA Capital Management, Janus Henderson Investors, Acuta Capital Partners, Ally Bridge Group, Avidity Partners, Ample Plus Fund, and CaaS Capital Management, and included existing investors Novo Holdings, Venrock, Lightstone Ventures, DROIA Ventures, Osage University Partners, as well as an undisclosed US-based, healthcare-focused fund.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.